PUBLICAÇÕES científicas

Brain delivery of microencapsulated GDNF induces functional and structural recovery in parkinsonian monkeys

Garbayo E (1), Ansorena E (2), Lana H (1), Carmona-Abellan MD (3), Marcilla I (4), Lanciego JL (5), Luquin MR (6), Blanco-Prieto MJ (7).
(1) Pharmacy and Pharmaceutical Technology Department, University of Navarra, 31008 Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IDISNA), 31008 Pamplona, Spain.
(2) Instituto de Investigación Sanitaria de Navarra (IDISNA), 31008 Pamplona, Spain; Biochemistry and Genetics Department, University of Navarra, 31008 Pamplona, Spain.
(3) Neurology Department, Clínica Universidad de Navarra, 31008 Pamplona, Spain; Neuroscience Division, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.
(4) Neuroscience Division, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.
(5) Instituto de Investigación Sanitaria de Navarra (IDISNA), 31008 Pamplona, Spain; Neuroscience Division, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain.
(6) Instituto de Investigación Sanitaria de Navarra (IDISNA), 31008 Pamplona, Spain; Neurology Department, Clínica Universidad de Navarra, 31008 Pamplona, Spain; Neuroscience Division, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain. Electronic address: rluquin@unav.es.
(7) Pharmacy and Pharmaceutical Technology Department, University of Navarra, 31008 Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IDISNA), 31008 Pamplona, Spain 

Revisão:Biomaterials

Data: 21/Set/2016

Neurologia [ES]

Glial cell line-derived neurotrophic factor (GDNF) remains the most potent neurotrophic factor for dopamine neurons. Despite its potential as treatment for Parkinson's disease (PD), its clinical application has been hampered by safety and efficacy concerns associated with GDNF's short in vivo half-life and with significant brain delivery obstacles.

Drug formulation systems such as microparticles (MPs) may overcome these issues providing protein protection from degradation and sustained drug release over time.

We therefore sought to evaluate the efficacy and safety of GDNF delivered via injectable biodegradable MPs in a clinically relevant model of PD and to investigate the mechanism contributing to their beneficial effects.

MPs were injected unilaterally into the putamen of parkinsonian monkeys with severe nigrostriatal degeneration. Notably, a single administration of the microencapsulated neurotrophic factor achieved sustained GDNF levels in the brain, providing motor improvement and dopaminergic function restoration.

This was reflected by a bilateral increase in the density of striatal dopaminergic neurons 9 months after treatment. Moreover, GDNF was retrogradely transported to the substantia nigra increasing bilaterally the number of dopaminergic and total neurons, regardless of the severe degeneration. GDNF-MP injection within the putamen elicited no adverse effects such as immunogenicity, cerebellar degeneration or weight loss.

MPs are therefore a safe, efficient vehicle for sustained protein delivery to the brain, supporting the therapeutic benefit of GDNF when encapsulated within MPs for brain repair. Overall, these findings constitute important groundwork for GDNF-MP clinical development.

CITAÇÃO DO ARTIGO  Biomaterials. 2016 Sep 21;110:11-23. doi: 10.1016/j.biomaterials.2016.09.015

tal vezLE INTERESE

QUE TECNOLOGIA UTILIZAMOS? 

A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OS NOSSOS
PROFISSIONAIS

Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.

Imagen profesionales de la Clínica Universidad de Navarra

RAZÕES PARA VIR
À CLÍNICA

Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.

Imagen del edificio de la Clínica Universidad de Navarra